Christine Chung, MD
Enriched profileChair, Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center · Moffitt Cancer Center
Christine Chung is Chair, Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center at Moffitt Cancer Center. OpenAlex indexes 680 publications with 28,625 citations (h-index 68); ClinicalTrials.gov lists 16 registered studies with this person as an investigator.
Data verified 17 Oct 2026
Overview
Updated 18 Oct 2026
Christine Chung, MD, is Chair, Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center. The public record shows 680 publications with 28,625 citations (h-index 68), centered on Head and Neck Cancer Studies, RNA modifications and cancer, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 16 registered clinical trials, industry payments reported by 13 companies, 3 NIH-funded awards (2015–2026).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Head and Neck Cancer Studies
- 16 registered trials on ClinicalTrials.gov
- Open Payments reporting from 13 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 27 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 199.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 16 registered studies on ClinicalTrials.gov. The most recent:
- Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Industry payments
Updated 18 Oct 2026
13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Regeneron Pharmaceuticals, Inc.Program year20256 payments
- HISTOSONICS, INC.Program year20252 payments
- Eisai Inc.Program year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
53.2%Opioid Agonist30.6%Oxycodone Hcl100%Part D≥17 patientsBenzodiazepine13.7%Lorazepam100%Part D<11 patients+ 1 more class in this area
Hormonal (systemic)
23.4%l-Thyroxine23.4%Levothyroxine Sodium100%Part D≥16 patientsMetabolism & gastrointestinal
14.5%Corticosteroid14.5%Prednisone100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
3 NIH research awards on record, funded 2015–2026 per NIH RePORTER. The latest:
- Ultrasensitive detection of circulating DNA methylation for head and neck cancer prognosis
H. Lee Moffitt Cancer Ctr & Res Inst
FY2026$712,674R01DE034377 - Ultrasensitive detection of circulating DNA methylation for head and neck cancer prognosis
H. Lee Moffitt Cancer Ctr & Res Inst
FY2025$716,123R01DE034377
Congress activity
Updated 18 Oct 2026
116 congress contributions (2004–2026) across AACE, AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract LB245: Collagen remodeling promotes a GPCR-mediated mechanosensory immune checkpoint in ADGRG1+ CD8+ T cells and serves as a spatial biomarker of response to immunotherapy
AACR Annual Meeting
AACR2026Co-authorLate-breaking - A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of HPV-negative, PD-L1–positive, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): FORTIFI-HN01.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial.
Journal of clinical oncology
Clinical Trial2026 - Evaluation of Neutrophil to Lymphocyte Ratio in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With a Combination of Cetuximab and Nivolumab in a Phase II Clinical Trial.
American journal of clinical oncology
Clinical Trial2026 - MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial.
Nature communications
Clinical Trial2026 - Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer.
Clinical cancer research
Clinical Trial2026 - Durable Complete Response of a Delta-Like Ligand 3 Expressing Head and Neck Neuroendocrine Carcinoma to Tarlatamab.
JCO precision oncology
Article2025
Most-cited works
by citation count (OpenAlex)- 01Human Papillomavirus and Survival of Patients with Oropharyngeal CancerArticle6,572 citations2010
- 02Chromosomal instability drives metastasis through a cytosolic DNA responseArticle1,581 citations2018
- 03Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-GalactoseArticle1,493 citations2008
- 04PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaArticle1,403 citations2018
- 05
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/cv/christine-chung-md-slash-2
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
wiza.co/d/moffitt-cancer-center/7a18/christine-chung
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →wiza.co ↗ - Other
onclive.com/authors/christine-chung-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Eastern Virginia Medical School
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com ↗ - Master's degree
Johns Hopkins University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com ↗
Media & interviews
press, podcasts and appearances- "Moffitt Doctor Uses Experience as an Immigrant to Better Treat Patients"
Spectrum News/Bay News 9 feature
2022verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →baynews9.com ↗ - "Once a Vocational Nomad, Christine H. Chung, MD, Now Works to Promote Patient-Centered Care in Head and Neck Cancer"
The ASCO Post narrative profile
2016verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Ignacio Wistuba, MD
Moffitt Cancer Center
Jonathan Strosberg, MD
Moffitt Cancer Center
Hatem Soliman, MD
Moffitt Cancer Center
Andrew Brohl, MD
Moffitt Cancer Center
Neal Futran, MD
University of Washington (UW Medicine)
Everett Vokes, MD
University of Chicago
Maura Gillison, MD
The University of Texas MD Anderson Cancer Center
Antonio Jimeno, MD
University of Colorado Cancer Center